Felzartamab

Phase 3Monoclonal antibody

Biogen

Felzartamab is one of 137 small molecule programs targeting Kidney Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

136

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Iga NephropathyActive, not recruiting

Lupus NephritisActive, not recruiting

Membranous NephropathyActive, not recruiting

Immunoglobulin a Nephropathy (igan)Recruiting

Antibody-Mediated RejectionEnrolling by invitation

Microvascular InflammationRecruiting

NephropathyActive, not recruiting

Kidney TransplantPhase 3

Active, not recruiting

Iga NephropathyPhase 2

Active, not recruiting

Lupus NephritisPhase 1

Active, not recruiting

Membranous NephropathyPhase 3

Active, not recruiting

Immunoglobulin a Nephropathy (igan)Phase 3

Recruiting

Antibody-Mediated RejectionPhase 3

Enrolling by invitation

Microvascular InflammationPhase 2

Recruiting

NephropathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Felzartamab

Biogen

Phase 3

1 2

Simulect

Novartis

Preclinical

15 3

Medrol

Pfizer

Preclinical

12 4

Zinbryta

Roche

Preclinical

6 5

Cysteine Hydrochloride

Novartis

Preclinical

1 6

Sensipar

Amgen

Preclinical

1 7

Radicava

Shionogi

Preclinical

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 9

Jardiance

Boehringer Ingelheim

Preclinical

3 10

Osmitrol

BB. Braun Medical Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Kidney Transplant

NCT06685757

Q1 2028

Phase 2Recruiting

Microvascular Inflammation

NCT07219043

Q1 2029

Phase 3Recruiting

Membranous Nephropathy

NCT06962800

Q2 2029

Phase 3Recruiting

Immunoglobulin a Nephropathy (igan)

NCT06935357

Clinical

Trials by Indication[1]

Antibody-mediated Rejection2 trials

Felzartamab in Late Antibody-Mediated Rejection

Completed·FFarsad Eskandary·Phase 2·NCT05021484·22 enrolled

An Open-Label Long-Term Extension Study of Felzartamab in Participants With Antibody-Mediated Rejection or Microvascular Inflammation Previously Enrolled in TRANSCEND or TRANSPIRE

Enrolling by invitation· Biogen logo

Biogen·Phase 3·NCT07444489·201 enrolled

Lupus Nephritis1 trial

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

Active, not recruiting·HHI-Bio, A Biogen Company·Phase 1·NCT06064929·14 enrolled

Kidney Transplant1 trial

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Recruiting· Biogen logo

Biogen·Phase 3·NCT06685757·120 enrolled

IgA Nephropathy1 trial

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Completed·HHI-Bio, A Biogen Company·Phase 2·NCT05065970·54 enrolled

Membranous Nephropathy1 trial

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Recruiting· Biogen logo

Biogen·Phase 3·NCT06962800·180 enrolled

2 more indications

Microvascular Inflammation1 trial

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI)

Recruiting· Biogen logo

Biogen·Phase 2·NCT07219043·81 enrolled

Immunoglobulin A Nephropathy (IgAN)1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)

Recruiting· Biogen logo

Biogen·Phase 3·NCT06935357·454 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Felzartamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Felzartamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Felzartamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Biogen

Felzartamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Q1 2029

Q2 2029

Trials by Indication[1]

Antibody-mediated Rejection2 trials

Lupus Nephritis1 trial

Kidney Transplant1 trial

IgA Nephropathy1 trial

Membranous Nephropathy1 trial

Microvascular Inflammation1 trial

Immunoglobulin A Nephropathy (IgAN)1 trial

References

Drug Info

Quick Facts

Related News